Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Melanoma × nilotinib × Clear all

Phase

Status

Completed 2 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7 Retroperitoneal liposarcoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Melanoma 1 Liposarcoma 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Acute 1 Leiomyosarcoma 1 Chondrosarcoma 1

Interventions

Nivolumab 22 pembrolizumab 16 Ipilimumab 13 Temozolomide 11 toripalimab 9 Biopsy 8 Dacarbazine 7 Blood Specimen Collection 7 Cyclophosphamide 6 trametinib 5 fludarabine 5 dabrafenib 5 camrelizumab 5 atezolizumab 5 durvalumab 4 binimetinib 4 aldesleukin 4 Interleukin-2 4 Injections 4 Gene Expression Profiling 4 Chemotherapy, Adjuvant 4 palbociclib 3 encorafenib 3 apatinib 3 Sorafenib 3 Introns 3 Cisplatin 3 Carboplatin 3 Canvaxin 3 Bevacizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01168050 2011-02-08

NILOMEL

Assistance Publique - Hôpitaux de Paris

Phase 2 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡